Skip Navigation


Cardiovascular Research Advance Access originally published online on August 7, 2009
Cardiovascular Research 2009 84(2):201-208; doi:10.1093/cvr/cvp274
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow All Versions of this Article:
84/2/201    most recent
cvp274v2
cvp274v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lacerda, L.
Right arrow Articles by Lecour, S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lacerda, L.
Right arrow Articles by Lecour, S.
Related Collections
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org.

Ischaemic postconditioning protects against reperfusion injury via the SAFE pathway

Lydia Lacerda*, Sarin Somers, Lionel H. Opie and Sandrine Lecour

Hatter Cardiovascular Research Institute, Cardioprotection Group, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Observatory 7925, Cape Town, South Africa

* Corresponding author. Tel: +27 21 406 6358; fax: +27 21 447 8789. E-mail address: lydia.lacerda{at}uct.ac.za

Aims: Ischaemic postconditioning (IPostC) is a powerful protective phenomenon that activates prosurvival intrinsic signalling cascades to limit reperfusion injury. We propose that IPostC confers its infarct-sparing effect via activation of the newly described prosurvival Survivor Activating Factor Enhancement (SAFE) pathway, which involves the activation of the cytokine tumour necrosis factor alpha (TNF{alpha}) and signal transducer and activator of transcription-3 (STAT-3).

Methods and results: Isolated ischaemic/reperfused hearts from TNF knockout, TNF receptor-1 knockout, TNF receptor-2 knockout, cardiomyocyte-specific STAT-3-deficient mice or their respective wild-type, (TNF-WT) or (STAT-3-WT), were postconditioned by ischaemic episodes (IPostC) or with exogenous TNF{alpha} (0.5 µg/L) (TNF-PostC) at the onset of reperfusion. IPostC reduced infarct size (IS) in TNF-WT and TNFR1–/– hearts (by 33 and 27%, respectively, P < 0.05), whereas hearts from TNF–/– or TNFR2–/– failed to be postconditioned. TNF-PostC reduced IS by 37% (P < 0.05) in STAT-3-WT hearts but failed to protect cardiac-specific STAT-3–/– hearts. Administration of wortmannin, an inhibitor of PI-3 kinase/Akt, or PD98059, an inhibitor of extracellular regulated kinase 1/2 (Erk1/2), during the postconditioning stimulus did not abolish the infarct-sparing effect of TNF-PostC. AG490, an inhibitor of STAT-3, abrogated the protective effect of TNF{alpha}. Western blot analysis did not demonstrate the involvement of Akt or Erk1/2 in TNF-PostC, whereas STAT-3 phosphorylation was increased in both IPostC and TNF-PostC.

Conclusion: The protective effect of the SAFE pathway is shown in IPostC, with the activation of TNF{alpha}, its receptor type 2, and STAT-3. This signalling cascade is activated independently of the well-known Reperfusion Injury Salvage Kinases (RISK) pathway, which involves the kinases Akt and Erk1/2.

KEYWORDS Infarction; Ischaemia; Preconditioning; Postconditioning; Reperfusion


Time for primary review: 21 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Article

No RISK, no ... cardioprotection? A critical perspective
Gerd Heusch
Cardiovasc Res 2009 84: 173-175. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
Cardiovasc ResHome page
G. Heusch
No RISK, no ... cardioprotection? A critical perspective
Cardiovasc Res, November 1, 2009; 84(2): 173 - 175.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.